Dies ist eine Übersichtsseite mit Metadaten zu dieser wissenschaftlichen Arbeit. Der vollständige Artikel ist beim Verlag verfügbar.
Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)
249
Zitationen
18
Autoren
2018
Jahr
Abstract
The second International Consensus Conference on B3 lesions was held in Zurich, Switzerland, in March 2018, organized by the International Breast Ultrasound School to re-evaluate the consensus recommendations. This study (1) evaluated how management recommendations of the first Zurich Consensus Conference of 2016 on B3 lesions had influenced daily practice and (2) reviewed current literature towards recommendations to biopsy. In 2018, the consensus recommendations for management of B3 lesions remained almost unchanged: For flat epithelial atypia (FEA), classical lobular neoplasia (LN), papillary lesions (PL) and radial scars (RS) diagnosed on core-needle biopsy (CNB) or vacuum-assisted biopsy (VAB), excision by VAB in preference to open surgery, and for atypical ductal hyperplasia (ADH) and phyllodes tumors (PT) diagnosed at VAB or CNB, first-line open surgical excision (OE) with follow-up surveillance imaging for 5 years. Analyzing the Database of the Swiss Minimally Invasive Breast Biopsies (MIBB) with more than 30,000 procedures recorded, there was a significant increase in recommending more frequent surveillance of LN [65% in 2018 vs. 51% in 2016 (p = 0.004)], FEA (72% in 2018 vs. 62% in 2016 (p = 0.005)), and PL [(76% in 2018 vs. 70% in 2016 (p = 0.04)] diagnosed on VAB. A trend to more frequent surveillance was also noted also for RS [77% in 2018 vs. 67% in 2016 (p = 0.07)]. Minimally invasive management of B3 lesions (except ADH and PT) with VAB continues to be appropriate as an alternative to first-line OE in most cases, but with more frequent surveillance, especially for LN.
Ähnliche Arbeiten
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 · 13.213 Zit.
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
2005 · 7.605 Zit.
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
2002 · 6.513 Zit.
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 · 6.334 Zit.
Twenty-Year Follow-up of a Randomized Trial Comparing Total Mastectomy, Lumpectomy, and Lumpectomy plus Irradiation for the Treatment of Invasive Breast Cancer
2002 · 6.188 Zit.
Autoren
Institutionen
- University of Geneva(CH)
- Hôpital Beau-Séjour(CH)
- Walker (United States)(US)
- St George’s University Hospitals NHS Foundation Trust(GB)
- Memorial Sloan Kettering Cancer Center(US)
- Kantonsspital Baden(CH)
- Nike (United States)(US)
- Marienhospital Osnabrück(DE)
- Dietrich Bonhoeffer Klinikum(DE)
- Immunologie-Zentrum Zürich(CH)
- University Hospital of Bern(CH)
- Medical University of Vienna(AT)
- Ludwig-Maximilians-Universität München(DE)
- University of Bologna(IT)
- University of Basel(CH)
- University Hospital of Basel(CH)
- Kantonsspital St. Gallen(CH)
- Breast Center(CH)
- Université Paris Sciences et Lettres(FR)
- Institut Curie(FR)
- Engeriedspital(CH)
- University Hospital of Zurich(CH)